Detalhe da pesquisa
1.
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial.
Lancet Oncol
; 24(3): 273-285, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36858723
2.
Coamplification of miR-4728 protects HER2-amplified breast cancers from targeted therapy.
Proc Natl Acad Sci U S A
; 115(11): E2594-E2603, 2018 03 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-29476008
3.
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation.
Lancet Oncol
; 21(11): 1455-1464, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-33152285
4.
Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial.
Lancet Oncol
; 21(1): 33-43, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31838010
5.
Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer.
Breast Cancer Res
; 22(1): 120, 2020 11 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33138866
6.
Efficacy of deescalated chemotherapy according to PAM50 subtypes, immune and proliferation genes in triple-negative early breast cancer: Primary translational analysis of the WSG-ADAPT-TN trial.
Int J Cancer
; 146(1): 262-271, 2020 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31162838
7.
Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial.
Breast Cancer Res
; 21(1): 108, 2019 09 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-31533777
8.
Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2.
Oncologist
; 24(7): 893-900, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30679318
9.
HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial.
Lancet Oncol
; 18(4): 545-554, 2017 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-28238593
10.
Genefu: an R/Bioconductor package for computation of gene expression-based signatures in breast cancer.
Bioinformatics
; 32(7): 1097-9, 2016 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26607490
11.
Identification of ALK, ROS1, and RET Fusions by a Multiplexed mRNA-Based Assay in Formalin-Fixed, Paraffin-Embedded Samples from Advanced Non-Small-Cell Lung Cancer Patients.
Clin Chem
; 63(3): 751-760, 2017 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-28073897
12.
Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy.
BMC Med
; 13: 303, 2015 Dec 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-26684470
13.
Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial.
BMC Med
; 17(1): 8, 2019 01 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-30621698
14.
Management of early-stage HER2-positive breast cancer and attitudes towards HER2DX test in Spain: insights from a nationwide survey.
Clin Transl Oncol
; 2024 Apr 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38653928
15.
Metastatic site patterns by intrinsic subtype and HER2DX in early HER2-positive breast cancer.
J Natl Cancer Inst
; 116(1): 69-80, 2024 01 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37676829
16.
Cell-cycle inhibition and immune microenvironment in breast cancer treated with ribociclib and letrozole or chemotherapy.
NPJ Breast Cancer
; 10(1): 20, 2024 Mar 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-38448600
17.
A 14-gene B-cell immune signature in early-stage triple-negative breast cancer (TNBC): a pooled analysis of seven studies.
EBioMedicine
; 102: 105043, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38447275
18.
The LCS6 polymorphism in the binding site of let-7 microRNA to the KRAS 3'-untranslated region: its role in the efficacy of anti-EGFR-based therapy in metastatic colorectal cancer patients.
Pharmacogenet Genomics
; 23(3): 142-7, 2013 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-23324806
19.
Prognostic and Predictive Value of Immune-Related Gene Expression Signatures vs Tumor-Infiltrating Lymphocytes in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Correlative Analysis of the CALGB 40601 and PAMELA Trials.
JAMA Oncol
; 9(4): 490-499, 2023 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36602784
20.
HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1.
J Natl Cancer Inst
; 115(3): 332-336, 2023 03 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36576009